Interactive Journal of Medical Research最新文献

Background: The use of dietary supplements (DSs) can lead to an excessive intake of certain nutrients, posing potential health risks. However, studies are scarce on whether DS users adhere to recommended doses provided by the manufacturer and what factors are associated with overconsumption of DS.

Objective: By leveraging purchase history data to estimate DS use precisely, this study aimed to investigate the factors associated with DS consumption exceeding manufacturer-recommended doses and examine the prevalence of excess nutrient intake among DS users.

Methods: An online survey was conducted from November to December 2024 among 2002 adults (aged 18-74 years) with a history of buying one of the 25 major DS products and who had used it in the previous month or regularly. Self-reported daily DS consumption was assessed using a questionnaire and compared to the manufacturer-recommended doses indicated in the package. Using multivariate logistic regression analysis, the associations between DS consumption exceeding the manufacturer-recommended doses and sociodemographic factors were examined.

Results: The prevalence of DS users exceeding tolerable upper intake levels (ULs), defined according to the Dietary Reference Intakes for Japanese, was calculated based on vitamin and mineral intake from DS only. Consequently, 371 (18.5%) of the 2002 participants consumed DS above the manufacturer-recommended dose. Consumption of DS above the recommended dose was associated with middle-aged, part-time or full-time employment, use of tablet-form DS, especially single water-soluble vitamin tablets, use of DS for 6 months or more, and intentional consumption above the recommended dose. For 1705 individuals consuming DS with UL nutrients, 17.4% (n=297) exceeded the manufacturer-recommended dose. Of these, 61.9% (184/297) surpassed UL by ≥1 nutrient.

Conclusions: Middle-aged, part-time or full-time jobs, using tablet-form DS, and using DS for 6 months or more were associated with DS consumption exceeding the manufacturer-recommended dose, which may lead to excessive nutrient intake.

Background: Neurodegenerative diseases are a major and growing global health burden. Their pathogenesis is complex, and effective therapies remain limited. Gene editing and stem cell-based strategies are reshaping the therapeutic landscape. However, the field has not been systematically examined through bibliometric analysis.

Objective: We aimed to define the intellectual landscape of global research on gene editing and stem cell therapy for neurodegenerative diseases from 2005 to 2024, highlight evolving hotspots, track the field's evolution, and identify major bottlenecks limiting clinical translation.

Methods: We retrieved 1821 publications from the Web of Science Core Collection (2005-2024). We performed a multidimensional bibliometric analysis using CiteSpace and VOSviewer. We assessed publication output, country and institutional contributions, key authors and journals, co-cited references, and keyword networks. These analyses were used to track the field's evolution and pinpoint emerging themes.

Results: In total, 9978 researchers from 90 countries and 2515 institutions contributed to this literature. Annual publications increased from 28 in 2005 to 179 in 2024, with stepwise growth over time. The United States ranked first in output (n=780) and in citation impact (total local citation score=2784; total global citation score=40,009). China and India ranked second and fifth in output, respectively, but their average citation impact was lower than that of the leading countries. The University of California, San Francisco, and Johns Hopkins University remained consistently influential. Boulis NM, Bankiewicz KS, and Feldman EL were among the most prominent contributors. Molecular Therapy was the leading journal in this area. Keyword analyses pointed to a growing intersection between genetics and immunology. Major topics included nanotechnology-based delivery, adeno-associated virus vectors, small interfering RNA, intrathecal microsphere injection, autophagy, blood-brain barrier (BBB) targeting, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), and induced pluripotent stem cells. Burst detection highlighted "open label" as a recent hotspot. This likely reflects rising translational activity and early clinical testing.

Conclusions: The field is moving from technology development toward clinical translation. Anglo-American countries currently drive both productivity and influence. China and India contribute heavily to volume but need a stronger impact. CRISPR/induced pluripotent stem cell platforms and BBB-focused delivery remain central frontiers. The rise of "open-label" studies suggests accelerating clinical momentum. Future progress will require safer and more efficient delivery, clearer standards, and larger global consortia to harmonize protocols and speed translation.

Background: The rising cost of unscheduled acute health care, particularly for emergency department (ED) visits, poses significant financial burdens. In 2021, aggregate costs for treat-and-release ED visits in the United States accounted for an estimated US $80 billion, while the total annual cost of diabetes was US $412.9 billion in 2022-representing about 1 in every 4 health care dollars, 61% of which are directly linked to diabetes.

Objective: This study explores the impact of a mobile health (mHealth) intervention with augmented social support delivered via guided SMS text messaging on health care use among patients with diabetes through a secondary analysis of the TExT-MED+FANS (Trial to Examine Text-Messaging in Emergency Patients With Diabetes + Family and Friends Network Support) randomized controlled trial.

Methods: The trial involved 173 participants randomized into either a FANS mHealth-augmented social support or an active control group that received the same support curriculum via mailed pamphlet; "augmented" social support refers to recruiting both individuals with diabetes and a designated family member or friend ("supporter") to participate. Supporters in the FANS arm received structured SMS guidance on how to assist the participant with diabetes in managing their condition. Health care use outcomes, including ED visits, hospitalizations, and clinic visits, were compared between groups during and after the intervention period using linear regression models on change in health care visits in the last year, with subgroup analysis by participant sex and supporter relationship.

Results: Results showed significant reductions in acute unscheduled care visits for both groups during and after the intervention, with the FANS group experiencing a reduction of 1.04 visits during the intervention and 1.10 visits after the intervention, while the mailed pamphlet group had reductions of 1.47 and 1.53 visits, respectively (both P<.001). Clinic visits increased by 1.78 during the intervention phase (P=.01) but were not sustained postintervention. Hospitalizations modestly decreased in both groups, but the decrease was statistically significant only for the mailed pamphlet group (P=.002). Sex and supporter relationship differences were observed, with females supported by spouses in the active control group showing the largest decrease in unscheduled care visits.

Conclusions: The findings suggest that mHealth interventions combined with structured social support can improve diabetes management and reduce health care costs. Although these conclusions are specific to this study, they align with prior research demonstrating the benefits of social support and mHealth interventions. These findings may inform future programs, including the design of low-cost, scalable interventions in resource-limited settings.

Fibromyalgia is a prevalent musculoskeletal pain condition that causes major personal, social, and societal burden. Pharmacological therapies often provide only limited benefit, making multimodal approaches and self-management the cornerstones of care. Such strategies, spanning lifestyle modification, physical activity, psychoeducation, and cognitive-behavioral approaches, target the biopsychosocial complexity of fibromyalgia and promote sustainable coping. In parallel, digital health technologies are transforming how these interventions can be delivered and coordinated in the form of digital therapeutics. This viewpoint draws on a multiphase investigation to appraise the current and future landscape of fibromyalgia self-management in the digital era. Its objective is to present an evidence-based framework and recommendations to guide the development of a mobile health self-management program for patients with fibromyalgia. In phase 1, we conducted a review of international guidelines and randomized controlled trial-based systematic reviews addressing nondigital self-management interventions for fibromyalgia and related nociplastic pain conditions. In phase 2, we analyzed the content and certification status of currently available mobile and virtual health applications for fibromyalgia. In phase 3, we convened a multidisciplinary focus group of rheumatologists, patients, and digital health developers to identify priorities for translating evidence-based self-management content into mobile health formats. Collectively, we suggest that effective digital self-management for fibromyalgia should evolve beyond single-domain interventions toward validated, personalized, and interactive multimodal platforms. Virtual care may increasingly function at the point of care, linking monitoring, education, and behavioral support in one continuum.